When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21

Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al. 1 Shanley M. Daher M. Dou J. Li S. Basar R. Rafei H. Dede M. Gumin J. Pantaleón García J. Nunez Cortes A.K. et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024; 42: 1450-1466.e11https://doi.org/10.1016/j.ccell.2024.07.007 Abstract Full Text Full Text PDF Scopus (1) Google Scholar report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma. Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al. 1 Shanley M. Daher M. Dou J. Li S. Basar R. Rafei H. Dede M. Gumin J. Pantaleón García J. Nunez Cortes A.K. et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024; 42: 1450-1466.e11https://doi.org/10.1016/j.ccell.2024.07.007 Abstract Full Text Full Text PDF Scopus (1) Google Scholar report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDShanley et al.Cancer CellAugust 12, 2024